HAIFA, ISRAEL, May 27, 2015 — Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PLTR), a leading developer of placenta-based cell therapy products, today announced participation at two important conferences:
International Congress of Radiation Research Location: Kyoto, Japan
Date: May 27, 2015
Presentation title: The Mechanism of Action of Placenta Derived Cellular Therapy in Mitigation of Acute Radiation Syndrome
Presented by: Racheli Ofir, Ph.D., Vice President of Research & Intellectual Property
The Japanese government is focused on the development of treatments for Acute Radiation Syndrome (ARS), as is the U.S. National Institutes of Health. ARS is caused by exposure to high levels of radiation, and produces severe, sometimes lethal damage to the bone marrow and other physiologic systems and organs. Pluristem recently announced the results of an NIH study conducted in animals exposed to high levels of radiation: injection of PLX-R18 cells, as compared to injection of a placebo, resulted in a significant improvement in survival, as well as in the recovery of blood cell production after irradiation. These blood cells are necessary to resist infection, prevent hemorrhage, and transport oxygen throughout the body.
International Society for Cellular Therapy, 21st Annual Meeting Location: Las Vegas, Nevada
Date: May 28, 2015
First Session titled: Hot Topics in Process and Product Development; Particulates, Serum Free Media and Bioreactors
Chaired by: Ohad Karnieli, Ph.D., MBA, Vice President of Technology & Manufacturing Date: May 29, 2015
Second session titled: Translational Process Development
Chaired by: Ohad Karnieli, Ph.D., MBA, Vice President of Technology & Manufacturing
Advanced Therapy Medicinal Products Location: Amsterdam, Netherlands Date: June 3, 2015
Presentation title: Case Study: Comparability of MSC’s during Scaling Up – From Design to Approval
Presented by: Ohad Karnieli, Ph.D., MBA, Vice President of Technology & Manufacturing
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company’s patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company’s proprietary three-dimensional expansion technology and are an “off- the-shelf” product that requires no tissue matching prior to administration.
Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.
Contact:
Pluristem Therapeutics Inc. Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109
